End of the vincristine/steroid pulse era in pediatric ALL?, “trial and error” with abatacept in GVHD, and hemorrhage risk with dasatinib therapy

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Resilience Pivot_ The End of Just-in-Time 3 min · 24 Sep 2026 · Conspiracy Theories Exploring The Unseen

Rugby Daily | NZ to scrap Super Rugby teams? James Tracy's *dream* Leinster head coach 12 min · 24 Sep 2026 · OTB Rugby

Hog Heaven, MAGA Hell 52 min · 24 Sep 2026 · I've Had It

KFC and Gen Z, OAPs and ChatGPT & An Email to Jimmy Fallon. 34 min · 24 Sep 2026 · Ray D'Arcy Daily

Bonds, Stocks Drop as Yields Extend Rally 2 min · 24 Sep 2026 · WSJ Minute Briefing

Judge gives press a pass 4 min · 24 Sep 2026 · Wall Street Breakfast

Report any issue

Source

Recorded15 Jun 2023

Publisherfeeds.transistor.fm ↗

Handlerec:11742021

Show notes

In this week’s episode we will review no survival benefit for vincristine/steroid pulses in contemporary studies of childhood acute lymphoblastic leukemia (or ALL). Next, the rheumatology drug abatacept may be a promising strategy for the treatment of acute graft-versus-host disease (or GVHD). Finally, we'll discuss the hemorrhage risk of dasatinib therapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in